sur Beta Bionics
Xeris Biopharma Announces Collaboration With Beta Bionics for Bi-Hormonal Pump Development
CONCORD, MA – Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. This partnership focuses on the development and commercialization of a new glucagon formulation using Xeris' XeriSol™ technology, aimed for use in Beta Bionics’ bi-hormonal pump systems designed for diabetes management.
Paul R. Edick, Chairman and CEO of Xeris, expressed enthusiasm about partnering with Beta Bionics, emphasizing the rapid support Xeris plans to offer in this significant venture. Beta Bionics' CEO, Sean Saint, highlighted the operational analogy of insulin and glucagon to a car’s gas pedal and brakes, respectively, underscoring the advantages of their bi-hormonal system over traditional insulin-only treatments.
The licensing agreement stipulates that Xeris could receive development payments and royalties from future sales of their specially formulated glucagon for these innovative pump systems.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Beta Bionics